Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Subcutaneous on par with IV pembrolizumab for NSCLC
17 Jul 2025
bởiStephen Padilla
Pembrolizumab administered subcutaneously (SC) is noninferior to the intravenous (IV) strategy in terms of overall exposure and trough concentrations, with similar efficacy and consistent safety profiles in patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), reports a study.








